ShareValue.ai

ShareValue scores for 300584.SHE: Valuation 24, Quality 42, Growth 77, Health 37.

300584.SHE
SZSE

Nanjing Hicin Pharmaceutical Co Ltd

CN¥35.94(-2.92%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-8% to 11%
Valuation
24
Overvalued
Price vs Value
Quality
42
Moderate
Business Strength
Growth
77
Strong
Revenue & Earnings
Health
37
Stressed
Financial Stability
Momentum
78
Bullish
Price Trend

Company Details

About

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; and raw materials, intermediates, and other products. Its products are used in cardiovascular and cerebrovascular, diuretic, anti-infection, digestive system, immune regulation, hypoglycemic, orthopedics, and other treatment areas. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is headquartered in Nanjing, China. Address: No.1 Hengfa Road, Nanjing, China, 210046

Score Analysis

AI Investment Thesis

Data as of:Jul 7, 2026
|
Last calculated:Jul 7, 2026